QUECTEL-WIRELESS
15.11.2022 09:02:18 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT and automotive solutions provider, today announces the launch of its new AG18 module, one of the next generation of Cellular Vehicle-to-Everything (C-V2X) modules. Featuring PC5 direct communications, the module enables vehicles to effectively communicate with one another and with their surroundings, ensuring improved safety and traffic efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005192/en/
Quectel announces C-V2X module AG18 to enhance driving safety and efficiency (Graphic: Business Wire)
The AG18 supports vehicle-to-vehicle (V2V), vehicle-to-infrastructure (V2I) and vehicle-to-pedestrian (V2P) communications on the unified 5.9GHz intelligent transportation system (ITS) band without the need of a (U)SIM, cellular subscription, or network assistance.
In addition to superior C-V2X communication capabilities, the AG18 module features flexible positioning service options including L1+L5 dual frequency GNSS, Qualcomm Dead Reckoning (QDR3) and high-precision PPE (RTK) technologies, ensuring that global automotive OEMs and Tier 1 suppliers can leverage location technology appropriate to their application requirements.
“C-V2X has been accepted worldwide as a core technology to support high level ADAS and autonomous driving. The AG18 module will enable the large-scale commercial deployment of C-V2X around the globe,” said Norbert Muhrer, President and CSO of Quectel. “It provides enhanced PC5 direct communications and positioning capabilities while significantly reducing the total build cost. The AG18 has already been recognized by several well-known car brands and been selected for critical automotive applications in their next generation vehicles.”
Based upon the AEC-Q100 qualified Qualcomm SA415M chipset, the AG18 complies with the international IATF 16949:2016 automotive quality management system. It is designed for use in extremely harsh environments and provides superior ESD/EMI protection performance.
The AG18 is pin-to-pin compatible with Quectel’s previous-generation C-V2X module AG15, allowing existing OEM customer devices to migrate seamlessly and upgrade through a simple drop-in replacement that will greatly reduce their design cost and development time. Additionally, the AG18 includes multiple interfaces including PCIe, USB 3.0/2.0, SPI, I2C, UART, GPIO, ADC and 1pps, enabling customers to develop a wide range of applications including Telematics Control Unit (TCU), Telematics BOX (T-BOX), Virtual Box (V-BOX) and Roadside Unit (RSU).
As a global supplier of automotive solutions, Quectel has developed a rich C-V2X portfolio for automotive-related applications, including the C-V2X module AG18/ AG15, the C-V2X AP module AG215S, the AG52xR series of LTE-A + C-V2X modules as well as the AG55xQ series of 5G + C-V2X modules, which ensures technological continuity for future customer plans for intelligent cars and transport systems.
Together with C-V2X modules, Quectel also offers a variety of high-performance C-V2X antennas, already in use in the autonomous car market. The C-V2X antenna can be mounted on the upper side of front and rear windshields of the vehicle or hidden inside the shark fin antenna. Besides, Quectel’s C-V2X antenna can achieve two-way compensation for antenna signal loss, bringing excellent performance even when the harness length is more than 4 meters.
The AG18 C-V2X module will be on display at electronica 2022 in Munich at Hall B5 Stand 248, November 15-18 2022 with engineering samples available now.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005192/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom